← Eichor
Study identifier: NCT06825702 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

Condition: Macular Edema  ·  Sponsor: Kiora Pharmaceuticals, Inc.

PhasePhase 2
Planned participants28
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.

This description comes directly from the study's public registry record.

Talk to the study team

Claudia Gregorio-King  ·  +61 421 992 076  ·  clinical@kiorapharma.com

Always discuss trial participation with your own doctor first.

Locations (6)

Sydney Eye HospitalSydney, New South Wales, AustraliaRecruiting
Sydney West RetinaWestmead, New South Wales, AustraliaNot Yet Recruiting
Royal Adelaide HospitalAdelaide, South Australia, AustraliaNot Yet Recruiting
Hobart Eye SurgeonsHobart, Tasmania, AustraliaRecruiting
Centre for Eye Research AustraliaEast Melbourne, Victoria, AustraliaRecruiting
Lions Eye Institute LimitedNedlands, Western Australia, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06825702